Cocrystal Pharma Inc expected to post a loss of 73 cents a share - Earnings Preview

Cocrystal Pharma

17/03/2023 11:08

* Cocrystal Pharma Inc  COCP.OQ   COCP.O  is expected
to show no
change in quarterly revenue when it reports  results on March 21
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Cocrystal Pharma
Inc is
for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cocrystal
Pharma
Inc is $10​, above​ its last closing price of $1.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.48       -0.48      -0.70     Missed  -45.8
 Jun. 30 2022  -0.54       -0.52      -3.00     Missed  -477
 Mar. 31 2022  -0.36       -0.42      -0.48     Missed  -14.3​
 Dec. 31 2021  -0.48       -0.48      -0.48     Met     0
 ​​Sep.        -0.48       -0.48      -0.48     Met     0
 30 2021                                                
 Jun. 30 2021  -0.42       -0.42      -0.48     Missed  -14.3​
 Mar. 31 2021  -0.60       -0.54      -0.48     Beat    11.1
 Dec. 31 2020              -0.48      -0.24     Beat    50
 This summary was machine generated March 17 at 11:08 GMT.  All
figures in US dollars  unless otherwise stated